Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 30 2014
Print

Breaking News

Kristin Brooks
February 14, 2014
Will discontinue Phase II study in colorectal cancer  Read More »
Kristin Brooks
February 14, 2014
To provide preclinical drug development through to Phase I - IV trials  Read More »
Kristin Brooks
February 13, 2014
Revenues up 8% in the quarter   Read More »
Kristin Brooks
February 13, 2014
Revenues up 7% in the quarter driven by Culex sales  Read More »
Kristin Brooks
February 13, 2014
Licenses early-stage discovery program against an epigenetic drug target  Read More »
Kristin Brooks
February 13, 2014
Zieziula, Diaz, Buffington, Kuta, and Ruggiero bring extensive industry experience  Read More »
Kristin Brooks
February 13, 2014
UCB acquires fibrosis therapy program  Read More »
Kristin Brooks
February 13, 2014
Expands business platform in North America with Forest purchase  Read More »
Kristin Brooks
February 12, 2014
Leverages technologies and product pipelines aimed at advancing therapeutics  Read More »
Kristin Brooks
February 12, 2014
Seeks to develop innovative products to sell or out-license  Read More »
Kristin Brooks
February 12, 2014
PCS segment sales up 8% in the quarter  Read More »
Kristin Brooks
February 12, 2014
Achieves record contract revenues  Read More »
Kristin Brooks
February 12, 2014
Yeager brings more than 23 years of experience  Read More »
Kristin Brooks
February 12, 2014
Kile brings 27 years of industry experience  Read More »
Gil Roth
February 12, 2014
Focuses on three themes, streamlines informatics offerings  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On